TEAS RF New Application

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

---

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

Trademark/Service Mark Application, Principal Register

Serial Number: 88393507

Filing Date: 04/19/2019

To the Commissioner for Trademarks:

MARK: PEM (Standard Characters, see below )

The literal element of the mark consists of PEM.
The mark consists of standard characters, without claim to any particular font style, size, or color.

The applicant, Kintai Therapeutics, Inc., a corporation of Delaware, having an address of
      26 Landsdowne St, Suite 450
      Cambridge, Massachusetts 02139
      United States

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

       International Class 005:  Therapeutic products for the treatment of disease; pharmaceutical preparations for the treatment of disease; therapeutic products to modulate metabolism; pharmaceutical preparations and agents to modulate metabolism; agents that modulate metabolism for scientific and research use; therapeutic pharmaceuticals for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; pharmaceutical preparations for the treatment of disease, namely, autoimmune diseases and disorders, bone and joint diseases and disorders, cancer, cardiovascular diseases and disorders, gastro-intestinal diseases and disorders, hematologic diseases and disorders, infectious diseases, kidney diseases and disorders, lung diseases and disorders, metabolic diseases and disorders, muscle diseases and disorders, nephrology diseases and disorders, neurodegenerative diseases and disorders, neurologic diseases and disorders, ophthalmic disease and disorders, skin diseases and disorders; therapeutic pharmaceuticals for modulating metabolism; pharmaceutical preparations and agents to modulate metabolism; pharmaceutical agents that modulate metabolism for scientific and research use
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

       International Class 042:  Research and development in the field of computational biology, biotechnology and pharmaceuticals
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.


The applicant's current Attorney Information:
      Christina M. Licursi and Daryl Achilles, Michael A. Albert, Nicole Davis Amar, Eric L. Amundsen, Michael J. Attisha, C. Hunter Baker, Jason W. Balich, Melissa Beede, Cristin Berkey, Brandon S. Blackwell, Adam S. Boger, Joshua M. Brandt, David F. Cauble, Tani Chen, Yahua Chen, Thomas S. Chlebeck, Bryan S. Conley, Gregory F. Corbett, Elizabeth A. DiMarco, Heather J. DiPietrantonio, Stuart V. Duncan Smith, Roque El-Hayek, Neil P. Ferraro, Emma L. Frank, Thomas A. Franklin, Renée C. Fuller, Edward R. Gates, David S. Gesner, Richard F. Giunta, Matthew H. Grady, Patricia L. Granahan, Michael A. Greene, Eric P. Greenwald, James M. Hanifin, Jr., John S. Harmon, , Jason M. Honeyman, Gerald B. Hrycyszyn, Jeffrey D. Hsi, Elizabeth A. Hudson, Elisabeth H. Hunt, Robert E. Hunt, Robert A. Jensen, Marc S. Johannes, Oona M. Johnstone, Hunter D. Keeton, Jessamine M. Lee, Sardiaa S. Leney, Christina M. Licursi, Helen C. Lockhart, Chelsea Loughran, Ethan W. Marks, William R. McClellan, Gabriel J. McCool, Marie A. McKiernan, Amy J. McMahon, Andrea D. Merin, Kevin Mosler, James H. Morris, Michelle K. Nyein, Timothy J. Oyer, Zachary P. Piccolomini, Michael J. Pomianek, Randy J. Pritzker, Michael N. Rader, Daniel G. Rudoy, Edward J. Russavage, Eric J. Rutt, Anant K. Saraswat, Turhan F. Sarwar, Claire E. Schuster, Michael Siekman, Karan Singh, Amanda Slade, Laura B. Sole, Nathan R. Speed, George Stamatopoulos, Charles T. Steenburg, Stephanie G. Stella, John L. Strand, Andrew J. Tibbetts, Maria A. Trevisan, Michael J. Twomey, John R. Van Amsterdam, Ryan M. Van Olst, Janice A. Vatland, Jessica A. vonReyn, Robert H. Walat, Patrick R.H. Waller, Edmund J. Walsh, Jennifer J. Wang, Daniel T. Wehner, John L. Welch, Andrew W. Williams, Douglas R. Wolf, Daniel W. Young, Lock See Yu-Jahnes, Wei Zhang, Chelsea E. Witte-Garcia, Adam Z. Zeiger of Wolf, Greenfield & Sacks, P.C.      600 Atlantic Avenue
      Boston, Massachusetts 02210-2206
      United States
      617-646-8384(phone)
      (617) 646-8646(fax)
      cxltrademarks@wolfgreenfield.com (authorized)
The attorney docket/reference number is V03132000400.

The applicant's current Correspondence Information:

Christina M. Licursi

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

617-646-8384(phone)

(617) 646-8646(fax)

cxltrademarks@wolfgreenfield.com (authorized) E-mail Authorization: I authorize the USPTO to send e-mail correspondence concerning the application to the applicant, the applicant's attorney, or the applicant's domestic representative at the e-mail address provided in this application. I understand that a valid e-mail address must be maintained and that the applicant or the applicant's attorney must file the relevant subsequent application-related submissions via the Trademark Electronic Application System (TEAS). Failure to do so will result in the loss of TEAS Reduced Fee status and a requirement to submit an additional processing fee of $125 per international class of goods/services.

A fee payment in the amount of $550 has been submitted with the application, representing payment for 2 class(es).

Declaration

Declaration Signature
The attached signature image file:
\\TICRS\EXPORT17\IMAGEOUT17\883\935\88393507\xml1\RFA0003.JPG



Signatory's Name: Paul Peter Tak, MD, PhD
Signatory's Position: President & CEO
Payment Sale Number: 88393507
Payment Accounting Date: 04/19/2019

Serial Number: 88393507
Internet Transmission Date: Fri Apr 19 12:23:00 EDT 2019
TEAS Stamp: USPTO/BAS-XX.XXX.XX.X-201904191223002610
52-88393507-62023d29f30b7bbfa9c7b7697e75
ddaa93a5cfa7d872c54ba436a0be3a11208c75-C
C-9590-20190419120425289334